NEW YORK, November 4, 2016 /PRNewswire/ --
This morning, four equities are under evaluation on Stock-Callers.comtoday, and they are: Humana Inc. (NYSE: HUM), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Molina Healthcare Inc. (NYSE: MOH), and Actinium Pharmaceuticals Inc. (NYSE MKT: ATNM). These companies are part of the Healthcare sector which saw a slight change
Kentucky headquartered Humana Inc.'s stock finished Thursday's session 1.71% lower at $165.31. A total volume of 949,456 shares was traded, which was above their three months average volume of 936,230 shares. The Company's shares are trading below their 200-day moving average by 5.31%. Furthermore, shares of Humana, which together with its subsidiaries, operates as a health and well-being company, have a Relative Strength Index (RSI) of 28.36.
On October 13th, 2016, research firm RBC Capital Markets reiterated its 'Sector Perform' rating on the Company's stock with a decrease of the target price from $222 a share to $217 a share.
On October 31st, 2016, Humana expanded its Medicare Advantage network participation agreement with Jefferson Health, providing enhanced health care access to physicians, hospitals and specialists for approximately 9,000 Humana Medicare Advantage members in Greater Philadelphia. The contract will become effective January 1st, 2017 and adds Aria Health and Rothman Orthopaedic Specialty Hospital to the Humana-Jefferson Health agreement. The free research report on HUM is available at:
On Thursday, shares in California headquartered Aerie Pharmaceuticals Inc. ended the session at $32.85, down 2.23%. The stock recorded a trading volume of 727,339 shares. The Company's shares have gained 77.57% in the previous three months and 34.91% since the start of this year. The stock is trading 3.29% above its 50-day moving average and 63.36% above its 200-day moving average. Moreover, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have an RSI of 46.04.
On November 01st, 2016, research firm Aegis Capital initiated a 'Buy' rating on the Company's stock.
On November 02nd, 2016, Aerie reported GAAP net loss attributable to common stockholders of $23.8 million, or $0.81 per share, for Q3 2016 compared to $18.0 million and $0.69 per share for Q3 2015. The $23.8 million net loss attributable to common stockholders for Q3 2016 includes $23.3 million in operating expenses, reflecting $12.7 million in research and development expenses, and $10.6 million in general and administrative expenses. Total adjusted net loss for Q3 2016 was $19.7 million, and adjusted net loss per share was $0.67. As of September 30th, 2016, Aerie had cash, cash equivalents, and investments of $255.6 million. The complimentary report on AERI can be downloaded at:
California headquartered Molina Healthcare Inc.'s stock ended yesterday's session 1.58% lower at $53.01 with a total trading volume of 467,292 shares. Shares of the Company, which provides Medicaid-related solutions to meet the health care needs of low-income families and individuals; and to assist state agencies in their administration of the Medicaid program, are trading 5.36% below their 200-day moving average. The stock has an RSI of 31.96.
On October 27th, 2016, Molina Healthcare reported that total revenue for Q3 2016 was $4.5 billion, up 26% over Q3 2015. The company reported that aggregate membership increased 22% over Q3 2015. Earnings per diluted share dropped marginally to $0.76 in Q3 2016 from $0.77 in Q3 2015. Visit us today and download our complete research report on MOH for free at:
At the close on Thursday, shares in New York headquartered Actinium Pharmaceuticals Inc. recorded a trading volume of 571,106 shares. The stock finished 7.42% lower at $0.86. The Company's shares are trading below their 50-day moving average by 40.40%. Furthermore, shares of Actinium Pharma, which develops targeted payload immunotherapeutics for the treatment of advanced cancers, have an RSI of 24.91.
On October 31st, 2016, Actinium Pharma announced the appointment of Bernie Cunningham, Ph.D, to the position of Executive Director of Clinical Supply Chain and Logistics, and CMC Project Management. Dr. Cunningham will report to Kaushik J. Dave, Ph.D, Actinium Pharma's CEO, as a keystone hire in the Company's growing Supply Chain Team. Dr. Cunningham will have a leadership role, responsible for further establishment of the Company's supply chain infrastructure and related distribution strategies. Dr. Cunningham has approximately thirty years of experience in the pharmaceutical and biotechnology industries. She led teams and directed multiple projects in manufacturing, supply chain and QA/QC at companies including Mesoblast and OSI Pharmaceuticals. Get free access to your technical report on ATNM at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!